BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...in the clinic. While molecules targeting the renin-angiotensin...
BioCentury | Aug 29, 2019
Company News

Aug. 29 Company Quick Takes: EC approves Tecentriq for breast cancer, Giapreza for hypotension; plus Innovent reports Tyvyt sales

...to treat refractory hypotension in adults with septic or other distributive shock. FDA approved the renin-angiotensin...
BioCentury | Jul 27, 2018
Clinical News

Reata reports retained benefit in Phase II CKD trial

...Retained eGFR benefit is the key secondary endpoint. Patients are required to be on stable renin-angiotensin-aldosterone...
BioCentury | Jul 23, 2018
Clinical News

Reata gains on retained benefit in CKD trial, proposes follow-on

...Retained eGFR benefit is the key secondary endpoint. Patients are required to be on stable renin-angiotensin-aldosterone...
BioCentury | May 11, 2018
Company News

La Jolla in $125M royalty financing for Giapreza

...through tiered royalty payments on worldwide net sales of Giapreza angiotensin II. FDA approved the renin-angiotensin...
BioCentury | May 10, 2018
Financial News

La Jolla in $125M royalty financing for Giapreza

...through tiered royalty payments on worldwide net sales of Giapreza angiotensin II. FDA approved the renin-angiotensin...
BioCentury | Mar 16, 2018
Financial News

La Jolla prices $100.3M follow-on

...increase blood pressure in adults with septic or other distributive shock. The drug is a renin-angiotensin...
BioCentury | Mar 15, 2018
Financial News

La Jolla prices $100.3M follow-on

...increase blood pressure in adults with septic or other distributive shock. The drug is a renin-angiotensin...
BioCentury | Mar 2, 2018
Clinical News

La Jolla's Giapreza lowers distributive shock mortality in Phase III

...show a mortality benefit (see BioCentury, March 10, 2017 ). In December, FDA approved the renin-angiotensin...
...San Diego, Calif. Product: Giapreza angiotensin II (formerly LJPC-501) Business: Cardiovascular Molecular target: NA Description: Renin-angiotensin...
BioCentury | Feb 26, 2018
Clinical News

La Jolla's Giapreza lowers distributive shock mortality

...show a mortality benefit (see BioCentury, March 10, 2017) . In December, FDA approved the renin-angiotensin...
Items per page:
1 - 10 of 282